Top in cardiology: Highlights from the American College of Cardiology Scientific Session

Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.

The data were presented at the American College of Cardiology Scientific Session.

“This study offers clear confirmation ... of very large benefits on symptoms and physical limitations due to HF with semaglutide vs. placebo,” Mikhail Kosiborod, MD, FACC, FAHA, a cardiologist at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, told Healio.

It was the top story in cardiology last week.

In another top story, researchers found that younger women with anxiety or depression were more likely to develop conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes.

“While we often feel that young women are the ‘safe group’ with regard to CVD, our study suggests that if a younger woman has depression or anxiety, we should screen for CV risk factors to reduce her risk,” Giovanni Civieri, MD, a cardiologist and research fellow at Massachusetts General Hospital and Harvard Medical School and a doctoral student at the University of Padua in Italy, told Healio.

Read these and more top stories in cardiology below:

Wegovy improves symptoms, physical function for obesity-related heart failure with diabetes

Adults with obesity, heart failure with preserved ejection fraction and type 2 diabetes saw marked improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, despite less than typical weight loss. Read more.

Anxiety, depression may accelerate heart disease risk, especially for younger women

Younger women with a diagnosis of anxiety or depression are at markedly higher risk for developing conditions that increase CVD risk, such as hypertension, hyperlipidemia and diabetes, researchers reported. Read more.

Heart disease prevalence among former NFL players extremely common

A screening study presented at the American College of Cardiology Scientific Session showed that there is a high prevalence of unrecognized heart disease among former National Football League players. Read more.

Web app can help patients determine if they qualify for a statin without a prescription

New results from the TACTiC trial show the promise of technology to help individuals appropriately determine if they qualify for statin therapy without a prescription. Read more.

Twice-yearly injectable antihypertensive drug lowers BP at 6 months: KARDIA-2

A single subcutaneous dose of zilebesiran, an investigational RNA interference agent, significantly reduced 24-hour mean ambulatory and office systolic BP at 6 months vs. placebo when added to other antihypertensive therapy. Read more.